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Breast conserving surgery of impalpable breast lesions requires safe and effective localisation techniques. 
Wire localisation has traditionally been used, but has limitations. Newer techniques are now being 
introduced to mitigate this.  The iBRA-NET group aims to robustly evaluate these new techniques in well-
designed prospective studies.  We report the first phase of this evaluation, a survey to establish current 
practice and service provision of breast localisation techniques in the UK.  
Methods: 
A National practice questionnaire was designed using ‘SurveyMonkey®’ and was circulated to UK breast 
surgeons via the Association of Breast Surgery and the Mammary Fold. The questionnaire was live from 
6th October 2018 to 6th April 2019. Only one response per unit was requested to reflect the unit’s practice.  
Results: 
Complete responses were received from 98 breast units across the UK. Wires were the mostly commonly 
used localisation technique (n=82) with fewer units using Magseed® (n=9), Radioguided Occult Lesion 
Localisation (n=5) and Radioiodine Seed Localisation (n=2). There was significant variation in practice and 
logistics involved. Frequent delays and theatre overruns were reported in 39 and 16 units, respectively. 
The median satisfaction score of the current technique was 7 out of 10. The main perceived limitation of 
existing localisation methods was logistics affecting theatre scheduling and the main barrier to introducing 
a new technique was cost. 
Conclusion: 
Wires are currently the most commonly used localisation technique but are associated with significant 
logistical issues. Newer techniques may offer a better solution but will need robust evaluation before they 
are adopted to ensure safety and efficacy.  
 
   






Detection of smaller breast cancers has increased with widespread implementation of breast screening 
programmes and improvement in breast diagnostic imaging[1]. Down-staging of tumour size by the use 
of neo adjuvant systemic therapy is increasingly being used to facilitate breast conserving surgery of 
smaller lesions[2][3][4]. These lesions require image-guided localisation prior to breast conserving surgery 
so they may be safely removed.  
Historically, the majority of localisations have been performed by wire insertion under ultrasound or 
mammographic guidance. This has been the gold standard since its first introduction by Dodd in 1965[5]. 
Although the procedure is well tolerated and is thought to be cost effective, it has several limitations 
including interference in theatre scheduling, placement of incisions affecting cosmesis, wire migration and 
disruption, difficulties in locating the tip, depth sensing, re-excision rates and potentially poor 
acceptability to patients. Wire insertion on the day of surgery can cause additional patient stress and may 
lead to delays to surgery despite prior co-ordination between surgeons and radiologists[6][7][8][9][10]. 
Other impalpable lesion localisation techniques such as Radioguided Occult Lesion Localisation (ROLL) and 
Radioiodine Seed Localisation (RSL) have been used in some centres to overcome the disadvantages of 
wire localisation. However, they also have limitations, notable of which is the requirement for regulatory 
licences with their strict codes of practice[10][11][12]. 
The introduction of newer techniques like Radio Frequency Reflector (RFR) localisation and Magseed®  for 
impalpable breast lesion localisation may mitigate some of the limitations of conventional localisation 
techniques[13]. The RFR is a non-radioactive, electromagnetic tagging system. SAVI SCOUT (Cianna 
Medical, Aliso Viejo, CA) was the first RFR to be introduced. Another recent device is LOCalizer (Faxitron, 
Tucson, AZ). These are commercially available and approved by the US Food and Drug Administration[13]. 
Magseed® consists of an implantable 5mm paramagnetic iron oxide pellet and a magnetic probe 
(Sentimag®) for intra-operative lesion identification.  
While these new localisation devices may have many advantages, there is a need to robustly evaluate the 
new localisation devices before they become established in routine clinical practice. A study was designed 
by the iBRA-Net Localisation Steering Group to evaluate the safety and efficacy of current methods of 
localisation.  The study design has two phases. Phase 1 aims to survey the current practice and service 
provision of breast localisation across the United Kingdom (UK). Phase 2 includes prospective national 
audits of the currently used breast lesion localisation techniques and of newly introduced techniques as 
described above.  
We report the results of the Phase 1, national practice questionnaire of impalpable breast lesion 





The national practice questionnaire was developed by the study steering group to explore the current 
practice and relevant logistics involved in localising impalpable breast lesions within breast units in the 
UK. The questionnaire aimed to identify the techniques currently used, any perceived limitations, gauge 
desire for change to a new technique, and evaluate the effect of current localisation technique on patient 
pathways and logistics, including sentinel lymph node (SLN) injections. The respondents were also asked 
to rate their satisfaction about their current technique from a score of 0 to 10, with 0 being the least 
satisfied and 10, the most satisfied. The questionnaire was designed using ‘SurveyMonkey®’ and was 
piloted in three hospitals. Following the pilot in each hospital the questionnaire was revised based on 
qualitative feedback, to ensure that the questions asked were essential and that respondents could clearly 
identify the question and give clear responses. The finalised questionnaire was circulated through the 
iBRA-net group of UK breast surgeons via the Association of Breast Surgery (ABS) newsletter, social media 
and the Mammary Fold (UK organisation of breast surgery trainees). The questionnaire was completed 
online between 6th October 2018 and 6th April 2019. Only one response per unit was requested to reflect 
the practice of the unit as a whole rather than that of individual surgeons. Multiple responses from the 
same individual and from the same unit were excluded from the study. The most complete response was 
taken as that unit’s entry for the analyses. Non responding units were encouraged to respond to the 
questionnaire by repeated reminders on the ABS newsletter but were not directly approached. 




A total of 122 complete responses were received. This included multiple responses from four individuals 
and 20 breast units. In total, completed responses were obtained from 98 breast units. All the responses 
were from breast surgeons except one from a radiologist. Responses were received from all geographical 
regions in the UK (Table 1). 
Unit infrastructure and localisation technique: 
Of the 98 units that responded with a completed questionnaire, 85 were NHS breast screening units. All 
units, except one offered stereotactic localisations. Wire localisation was the predominant localisation 
technique for impalpable breast lesions that was used as the current standard in 82 breast units. The other 
techniques utilising radioactive substances were used in seven units. Amongst the respondents, 22 units 
had trialled Magseed®, and nine units were using Magseed® as their current localisation method. 
Unit volume and personnel: 
The number of impalpable lesion localisations performed by the units per year and the timing of 
localisations are shown in Table 1. Consultant radiologists primarily performed the localisations. In 57 
units localisations were also performed by radiographers.  
Localisation scheduling: 
The localisations were predominantly performed on the same day (Table 1). In the two units using RSL, 
Iodine seeds were placed 3-14 days prior to surgery. In four units using Magseed® as the current standard, 
localisations were performed in a two week window prior to surgery. 
Logistics:  
In a majority of units (60), patients moved to a different part of the same hospital building for surgery 
following localisation either by walking or assisted by a porter. In four units, localisations were also 
performed by breast surgeons in the operating theatre (Table 1). 
Theatre scheduling: 
In units, where breast localisation was performed on the day of surgery without sentinel lymph node (SLN) 
injection, the average time from patient arrival in the radiology suite to readiness for anaesthesia varied 
significantly. Approximately half of units (n=48) reported the average time required was between 60 to 
90 mins, resulting in the first patient requiring excision of an impalpable breast lesion being scheduled for 
surgery between 10 and 11am.  In these units, the localisations happened in the same building and 
patients usually walked or were being portered. The time taken was 90 to 120 mins in 15 units, and up to 
2 hours in 13 units. Six of these units had radiology suites in a different hospital site. This resulted in these 
patients being scheduled for surgery much later in the day (Table 1). 
SLN injection: 
In 54 breast units, radioisotope SLN injection was scheduled either the day of or the day before surgery, 
based on theatre scheduling. It was exclusively performed on the day of surgery in 25 units and the day 
before in 29 units. Breast surgeons from five units performed the SLN injection on the same day as surgery 
in the operating theatre or in the anaesthetic room. In a majority of the units (n=55), the injection was 
performed in the nuclear medicine department. In 11 units, it was administered in the radiology suite and 
in 18 units in a different hospital. Multiple locations for injections were described including; the breast 
unit, ward, day unit admission suite and breast outpatient clinic room (Table 1). 
Satisfaction with current localisation method: (Figure 1) 
The median score of the responses was 7. Both the RSL units who responded to this questionnaire gave a 
satisfaction score of 10. Of the remaining 21 who gave high scores of 9 and 10, two were using Magseeds® 
and the remaining 19 were using wires as their current localisation technique. 
Limitations of current localisation technique: 
The perceived limitations reported by individual units regarding their current localisation technique are 
summarised in Table 2. These mainly included logistical issues affecting theatre scheduling (n=74); 
concerns that the technique was not patient friendly (n=51), issues relating to accurate localisation of the 
lesion including wire migration (n=46); difficulty locating the tip of the wire (n=42) and excising too much 
tissue (n=39). Cost and concern about depth sensing in dense and large breasts were highlighted by units 
using Magseeds®. 
Desired improvements and barriers to change: 
Improvements that the respondents felt would be desirable in a new localisation technique and the 
reasons that prevented trial and adoption of a new technique are listed in Table 2. The main barriers to 
change were cost (n=63) with concerns about licencing also highlighted in units wishing to change to a 
radioactive technique. 
Preference to change: 
Units were asked to indicate if they would consider changing localisation technique and which, if any 
alternative they would prefer. Slightly more than half of the respondents (56%) wished to change their 
localisation technique. In this cohort, 60% (n=49) of the wire localisation units preferred a change to a 
different technique. The stated preferences were to Magseed® in 38 units and RSL in eight, ROLL in two 
and radiofrequency technique in one. Twenty-one units did not wish to change, and 22 were undecided.  
Discussion:  
This study provides a valuable insight into the current practice of impalpable breast lesion localisation in 
the UK. It provides information on the different localisation techniques currently used and the logistics 
involved.  It has also highlighted a significant proportion of units are dissatisfied with their current 
localisation technique with more than half of units wishing to change techniques to improve workflow 
and patient care. As the survey was completed by two-thirds of breast units this is likely to be 
representative of UK practice as a whole. This is the first worldwide and UK-based survey of non-palpable 
breast lesion localisation.  
Wire localisation is still the predominant technique and the current standard for impalpable breast lesion 
in 85% of the units that responded. Wire insertions performed on the day of surgery or the day before 
adds pressure on the radiology team to provide these services at specified times. Localisations are 
increasingly performed by advanced practice radiographers (57 units) to support this as there is a UK wide 
shortage of consultant breast radiologists[14]. Theatre scheduling is affected in units practicing same-day 
localisations with potential for delay. This also has cost implications, but more importantly adds extra 
stress and anxiety to the patients on the day of their surgery. There was also significant variation in 
practice of SLN injections contributing to additional theatre delays. 
Each localisation technique has its inherent drawbacks but many of these such as wire displacement and 
difficulty locating the wire tip are associated with wire localisations. In units using Magseed®: cost, 
learning curve and depth sensing in dense and large breasts were mentioned as potential concerns. 
Concerns about regulatory licenses were expressed by units practicing ROLL or RSL.  
Forty three (44%) respondents were undecided or did not want to change their localisation technique. 
Amongst the units who did not want to change were the units using RSL and Magseed® (except one), 
including 11 wire localisation units. Twenty units were undecided which could be due to a multitude of 
factors as elicited under ‘Barriers to change’. This shows that a small proportion of wire users are content 
not to change, while those undecided will be evaluating the new technologies as their use and outcome 
data matures. 
Newer technologies are emerging to mitigate the drawbacks of current localisation techniques. RFR 
localisation is a relatively new technique. It has advantages over wire localisation and radioactive 
localisation techniques as it can provide separate radiology and surgery scheduling without the need for 
stringent regulatory compliance. The other advantages are (i) multiple reflectors can be deployed as each 
reflector has a unique tag[13] (ii) RFR device is MR conditional and causes minimal signal void artefact as 
compared with Magseed®[15]. The disadvantages are relatively large size of the SAVI SCOUT® device 
(12mm) compared to Magseed® (5mm) and RSL (4.5mm). The LOCalizer® measures 11mm.  These 
techniques may be more patient friendly and facilitate both more efficient theatre scheduling and use of 
radiology time but large-scale prospective multicentre trials are needed to establish their safety and 
efficacy. 
The study has limitations which require consideration. This was a survey of current UK practice and actual 
practice may vary from that reported. In addition, despite a good response rate, does not capture all 
practice across the UK, potentially introducing selection bias. Despite these limitations, this survey 
provides a valuable insight into the current practice of breast lesion localisation and also about sentinel 
lymph node practice across the UK. The questionnaire reflects only the UK and NHS based practice. Many 
of the results will be transferable to other healthcare systems and countries, but the drivers for change, 
both logistically and financially will vary between healthcare systems. 
Robust evaluation of new techniques will be vital and phase 2 of this study involves a National prospective 
audit of current localisation techniques and the newly introduced techniques with a primary endpoint of 
identification and excision of the index lesion. The main secondary endpoints are accuracy of localisation, 
complication and re-operation rate. Data is currently being collected from multiple participating centres 
across the UK and the results will be presented in the near future. 
 
Conclusion: 
Wire localisation is the most commonly used localisation technique for excision of impalpable breast 
lesions. It has its own limitations and newer techniques are being introduced to mitigate this. This national 
practice questionnaire of impalpable breast lesion localisation in the UK has shown wide variation in 
practice; perceived limitations of conventional localisation techniques and has highlighted a desire in 
many units to change.  Any new localisation devices must be robustly evaluated and prospective audits 
that are ongoing will provide evidence to support future change. 
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East Midlands 7 







Central South East (Wessex) 




















100 - 200 45 
200 - 300 19 
300 - 400 9 









Surgeon (Intra op USS in theatre) 4 








Same day of surgery 
 
67 
Either same day or day before 25 
2 to 14 days prior to surgery 
 
6 
Logistics - Following localisation, where does the 
patient’s surgery take place? 
 
 
Different part of the same hospital building 
 
60 
Different building on same hospital site 17 
A different hospital site 17 
Same place as localization 
 
4 







Hospital transport 4 




Time to arrive in theatre after same day localisation 
without SLN injection 
 
 
30 to 60 mins 
 
28 
60 to 90 mins 48 




What time could you schedule the first localization 




8 to 9am 
 
15 
9 to 10am 26 
10 to 11am 42 
11 to 12am 11 
After 12 noon 
 
4 
When is the SLN injection performed?  
 
Same day (A) 
 
25 
Day prior (B) 29 
A or B 
 
54 
Where is the SLN injection performed?  
 
Nuclear medicine department 
 
55 
Radiology suite 11 
Different hospital 18 
Other locations 4 
Operating theatre / anaesthetic room 
 
5 





Once or twice a week 33 









Once or twice a week 15 
























Perceived limitation of current localisation technique Breast units 
 
Logistical issue affecting theatre scheduling 
 
74  
Not patient friendly 51  
Migration of the localisation wire 46  
Difficulties locating the tip of the wire 42  
Excising too much tissue 39  
Interference and delays when combined with SLN localisation 33  
Depth sensing 29  
Concern about not excising the index lesion 20  
No concerns 13 
X-ray / USS visibility 12 
Localisation to be within < 24 hrs ( Eg ROLL) 10 




Preferred improvement in a new localisation technique  
 
Improved patient experience 
 
69 
Better organization of lists / theatre scheduling 67 
Better use of radiology time 65 
Accuracy in localisation 55 
Decrease in re-excision rates 42 
Smaller specimen weight 41 
Cost efficiency 34 
No regulatory licences 20 
 





Organisational issues (Effecting management change) 60  
Training 39  
Learning curve 38  
Evidence base 31  
Time to effect change 30  
Aversion to change in the unit 16  
 
 
Table 2 –Perceived limitations of current localisation technique, preferred improvements and barriers to 



































0 - least satisfied
10 - most satisfied
